<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370470</url>
  </required_header>
  <id_info>
    <org_study_id>C-000619</org_study_id>
    <nct_id>NCT04370470</nct_id>
  </id_info>
  <brief_title>Development of Assessments for Later Stage HD</brief_title>
  <acronym>LSA</acronym>
  <official_title>Development of Assessments for Later Stage Huntington's Disease: UHDRS Structured Interview of Function and HD Clinical Status Questionnaire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHDI Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHDI Foundation, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Later Stage HD Assessments (LSA) is an observational, multinational study aiming at
      developing two assessments that can be used to measure critical milestones and events during
      the later stages of Huntington's disease (HD). An important aspect of the evaluation will be
      to assess whether the assessments can be administered to a companion either in-person or
      remotely (i.e. by phone contact with the companion). Therefore, these assessments will be
      evaluated for their internal consistency, reliability and validity. Once established, these
      assessments may be incorporated into a large scale, global observational study of HD and/or
      other HD clinical studies as well as use them for planning clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the internal consistency, reliability and
      validity of two assessments: (1) UHDRS Structured Interview of Function (SIF) that
      incorporates the UHDRS Total Functional Capacity, Functional Assessment Scale, and
      Independence Scale (UHDRS TFC, FAS and IS), and (2) the HD Clinical Status Questionnaire
      (HDCSQ). There will be two study parts: Part 1 will measure the performance of the UHDRS SIF
      assessment compared to the original UHDRS TFC, FAS and IS using a cross-over design by
      collecting data from the Manifest HD gene expansion carrier participants (Manifest HDGEC
      Participants) and their companions (Companion Participants) via an in-person baseline visit
      and a follow-up visit by phone. Part 2 will assess the UHDRS SIF and the HDCSQ using a
      cross-sectional design by collecting data from the Companion Participants via a follow-up
      visit by phone. Participants of Part 1 are eligible to participate in Part 2.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>21 Days</target_duration>
  <primary_outcome>
    <measure>The UHDRS SIF ratings</measure>
    <time_frame>3 weeks</time_frame>
    <description>The equivalence of the original UHDRS function scales (TFC, FAS and IS) and the UHDRS SIF will be evaluated using a cross-over design study, with two baseline measurements and one follow up measurement. We will use ICC (Intraclass Correlation Coefficient) and Lin's correlation coefficient will be used to measure the agreement between raters across Participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinimetric properties of the UHDRS SIF</measure>
    <time_frame>3 weeks</time_frame>
    <description>To assess the clinimetric properties of the UHDRS SIF we will use Classical Test Theory (CTT) and Item Response Theory (IRT)</description>
  </primary_outcome>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Huntington Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Manifest HDGEC Participants: Manifest HDGEC Participants must be participants in the
        Enroll-HD study. Manifest HDGEC Participants will be recruited from English-speaking study
        sites participating in the Enroll-HD study.

        Companion Participants: Companions Participants will be identified for Manifest HDGEC
        Participants and asked to participate. A Companion Participant's participation for a
        Manifest HDGEC participant is mandatory.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must meet all the following inclusion criteria to participate in this study:

        All Participants

          1. Individual of either gender

          2. Fluent in English

          3. Must be willing and able to provide informed consent or have a legal representative
             willing and able to provide assent

        Manifest HDGEC Participants

          1. Must be an active participant in the Enroll-HD study. An active participant is defined
             as a participant who has successfully enrolled in the Enroll-HD study and completed
             the Enroll-HD study baseline visit.

          2. Age≥20 years

          3. CAG repeat length≥36

          4. DCL=4

          5. Inclusion score of 16 at the time of the participant's most recent Enroll-HD study
             visit (for inclusion score calculation, see Appendix A - Inclusion Score Calculation)
             Companion Participants

        1. Age≥18 years 2. A person who, in his/her opinion, has sufficient interface and knowledge
        of the Manifest HDGEC Participant's capabilities and daily activities 3. Acceptable to the
        Manifest HDGEC Participant and the Site Investigator or the Site Investigator's designees

        Exclusion Criteria:

        People who meet the following criteria will be excluded from participating in this study:

          1. Individuals with choreic movement disorders in the context of a laboratory verified
             non-expansion mutation for the Huntingtin gene

          2. Manifest HDGEC Participants with Juvenile-onset HD (rater estimate of age of onset &lt;20
             years old)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jamie Levy</last_name>
    <phone>+1-609-945-9600</phone>
    <email>jamie.levey@enroll-hd.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jenna Smith</last_name>
      <phone>205-996-2807</phone>
      <email>jltidwell@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Sung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regents of the University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Chase Snell</last_name>
      <phone>858-249-0569</phone>
      <email>cmsnell@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Jody Corey-Bloom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regents of the University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Aaron Fisher</last_name>
      <phone>310-206-8153</phone>
      <email>adfisher@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Perlman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center, P.C</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jessica Jaynes</last_name>
      <phone>303-357-5456</phone>
      <email>jaynes@kumarneuro.com</email>
    </contact>
    <investigator>
      <last_name>Rajeev Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush Universiity Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alice Negron</last_name>
      <email>alice.negron@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Hall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hereditary Neurological Disease Centre, Inc.</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Gregory Suter</last_name>
      <phone>316-609-3020</phone>
      <email>hndcentre@aol.com</email>
    </contact>
    <investigator>
      <last_name>William Mallonee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Stacey K Barton</last_name>
      <phone>314-362-3471</phone>
      <email>bartons@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Joel S Perlmutter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Elizabeth Huitz</last_name>
      <phone>615-936-1007</phone>
      <email>elizabeth.huitz@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Daniel O Claassen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Leigh Beth Latham</last_name>
      <phone>206-685-6602</phone>
      <email>btlatham@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Anny Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Chancellor, Masters and Scholars of the University of Cambridge</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0PY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Priya Rogers</last_name>
      <phone>01223 331160</phone>
      <email>pr466@cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Roger Barker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiff University</name>
      <address>
        <city>Wales</city>
        <state>Cardiff</state>
        <zip>CF144XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarah Irvine</last_name>
      <phone>01392406979</phone>
      <email>sarah.irvine@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Timothy Harrower, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poole Hospital NHS</name>
      <address>
        <city>Poole</city>
        <state>Dorset</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Annemieke Fox</last_name>
      <email>annemieke.fox@poole.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>John Burn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leicestershire Partnership NHS Trust</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE2 2PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Dawn Freire-Patino</last_name>
      <phone>01162951996</phone>
      <email>dawn.freire-patino@leicspart.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Reza Kiani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <state>Leicester</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Zara Skitt</last_name>
      <phone>01865231556</phone>
      <email>zara.skitt@ouh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Sarsha Wilson</last_name>
      <phone>0186521080</phone>
      <email>sarsha.wilson@ouh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Armstrong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northumberland, Tyne &amp;Wear NHS Foundation Trust of St. Nicholas Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne &amp; Wear</state>
        <zip>NE6 4QD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarah Edwards</last_name>
      <phone>441912467392</phone>
      <email>sarah.edwards@ntw.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Suresh Komati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham and Solihull Mental Health NHS Foundation</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B152FG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Ellice Parkinson</last_name>
      <phone>01213014337</phone>
      <email>ellice.parkinsons@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Hugh Rickards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <state>Yorkshire</state>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Callum Schofield</last_name>
      <phone>01133924679</phone>
      <email>callum.schofield@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Emma Hobson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Plymouth NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Jemma Inches</last_name>
      <phone>0175243845</phone>
      <email>jinches@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Rupert Noad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Pauline Bayliss</last_name>
      <phone>0114 2260828</phone>
      <email>pauline.bayliss@sch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Oliver Quarrell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CHDI</keyword>
  <keyword>Huntington Disease</keyword>
  <keyword>Huntington's Disease</keyword>
  <keyword>Huntington's Disease Later Stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

